Skip to main content

Table 8 Risk for primary, secondary, and tertiary individual CV end points with linagliptin versus total comparators based on Cox proportional hazards model

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

 

Cox HR (95% CI)

Primary end point

 

CV death, MI, stroke, or

0.78 (0.55–1.12)

UAP with hospitalization

 

Secondary end points

 

CV death, stroke, or MI

0.74 (0.49–1.13)

All major CV events

0.82 (0.61–1.09)

FDA-custom MACE

0.70 (0.45–1.08)

Tertiary end points

 

CV death

1.04 (0.42–2.60)

Non-fatal MI

0.86 (0.47–1.56)

Non-fatal stroke

0.34 (0.15–0.75)

TIA

0.09 (0.01–0.75)

UAP with hospitalization

1.08 (0.56–2.06)

Hospitalization for CHF*

1.04 (0.43–2.47)

Total mortality

0.89 (0.45–1.75)

  1. CHF, congestive heart failure; CI, confidence interval; CV, cardiovascular; FDA, Food and Drug Administration; HR, hazard ratio; MACE, major adverse CV events; MI, myocardial infarction; TIA, transient ischemic attack; UAP, unstable angina pectoris.
  2. *Includes data only from 8 trials with prospective independent adjudication of hospitalization for CHF (n = 3314).